GTC Biotherapeutics Announces Time Change for Webcast of Corporate Presentation at SG Cowen & Co. 6th Annual Global Health Care Conference
Posted on: Friday, 4 November 2005, 09:00 CST
GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today a time change for the presentation to be given by Geoffrey Cox, Ph.D., Chairman and CEO of the Company, at the SG Cowen & Co. 6th Annual Global Health Care Conference. The presentation is now scheduled for 11:30 a.m. Central European Time (5:30 a.m. Eastern Time) on Thursday, November 10, 2005. The conference is being held at the Hilton Diagonal Mar, Barcelona, Spain.
The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC's lead program is ATryn(R), its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn(R) in patients with a hereditary antithrombin deficiency. In addition to the ATryn(R) program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.
Source: Business Wire
Related Articles
- AVerMedia(R) Information, Inc., USA Announces New National Sales Director for the Presentation Products Division
- VGX Pharmaceuticals Presents Non-Human Primate Study Data at AIDS Vaccine 2008 Conference
- King Pharmaceuticals Files Citizen Petition With FDA Asserting ZymoGenetics Has Not Submitted Adequate Data for Approval of Its Recombinant Thrombin Product
- Natrol Sponsors Seminar on First Weight Control Ingredient With Two FDA-Permitted Claims, Presents Products for Weight Management at 2007 Expo West
- eFoodSafety.Com, Inc. Enters Biotech Arena With Revolutionary Lyme Disease Product; Human Clinical Trials Currently Underway
- HandySoft Global Presents Product Roadmap for 2006
- Review of the First Commercially Approved Gene Therapy Product Presented in Human Gene Therapy
- XOMA Licenses BCE Technology for Recombinant Protein Production to Wyeth
- The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated With VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared With Other Apolipoproteins
- Interlink Electronics to Showcase Award-Winning Personal Presentation Products at InfoComm 2004
 |
 |
User Comments (0)
RSS Feeds